BioLASCO Taiwan Co., Ltd.

6662

TW0006662000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-30 EDT			5-day change	1st Jan Change
37.9 ^TWD	+2.71%		+2.43%	+14.16%

05-14	BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

BioLASCO Taiwan Co., Ltd. Appoints Stacey Yu as Corporate Governance Officer

March 25, 2021 at 06:29 am

BioLASCO Taiwan Co., Ltd. appointed Stacey Yu, CFO as Corporate Governance Officer, effective March 25, 2021.

Latest news about BioLASCO Taiwan Co., Ltd.

BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-19	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend	23-07-31	CI
BioLASCO Taiwan Co., Ltd. Announces Change of Remuneration Committee	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Announces Change of Audit Committee	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Announces Board Changes	23-06-12	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-24	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-04	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend, Payable on August 26, 2022	22-07-05	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI
BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-05	CI
BioLASCO Taiwan Co., Ltd. Announces CEO Changes	21-11-05	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-05	CI
BioLASCO Taiwan Co., Ltd. Announces Cash Dividend, Payable on September 22, 2021	21-08-05	CI
BioLASCO Taiwan Co., Ltd. Elects Liu, Wei-Ming as Natural-Person Director	21-08-05	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI
BioLASCO Taiwan Co., Ltd. Appoints Stacey Yu as Corporate Governance Officer	21-03-25	CI
BioLASCO Taiwan Co., Ltd. Renews Ten-Year Distribution and Propagation Agreement with Charles River Laboratories International, Inc	21-03-18	CI
BioLASCO Taiwan Co., Ltd. Announces Resignation of Chen,Chien-Chang as Director	21-03-03	CI
Biolasco Taiwan Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-11	CI

Chart BioLASCO Taiwan Co., Ltd.

Duration

Period

More charts

BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOLASCO TAIWAN CO., LTD.	+14.16%	29.09M
MODERNA, INC.	+17.83%	45.51B
IQVIA HOLDINGS INC.	-9.37%	38.52B
LONZA GROUP AG	+38.08%	38.13B
ALNYLAM PHARMACEUTICALS, INC.	+26.45%	30.74B
CELLTRION, INC.	-8.64%	26.03B
ICON PUBLIC LIMITED COMPANY	+11.83%	25.92B
UNITED THERAPEUTICS CORPORATION	+46.12%	14.13B
MEDPACE HOLDINGS, INC.	+33.78%	12.73B
BIO-TECHNE CORPORATION	-7.30%	11.29B